REN and hydrops fetalis: Despite the presence of heterogeneity within the various subtypes of HF, current treatment options mainly target the activation and consequences of the renin–angiotensin–aldosterone system (RAAS), with success in decreasing mortality and morbidity in HF with reduced ejection fraction (HFrEF), but not HF with preserved ejection fraction (HFpEF) [2].